二酶抑制和dipiridamole动态衍生物的免疫活性
Artur Martynov1, Boris Farber2, Alexander Katz3
1Laboratory and Clinical Department of Molecular Immunopharmacology, Mechnikov Institute of Microbiology and Immunology of National Academy of Medical Sciences of Ukraine, 61000 Kharkiv, Ukraine.
Current issues in molecular biology
|July 23, 2025
概括
研究人员开发了新的二甲基衍生物 (DDD),可以有效抑制固酶 (PDEs) 并恢复小鼠的免疫力. 这些动态组合衍生物与纯二皮里达摩尔相比,显示出增强的抗病毒和抗腹特性.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 药物设计 药物设计
背景情况:
- 迪皮里达摩尔 (DIP) 具有与固酶 (PDE) 抑制相关的药理特性,包括对流感,SARS-CoV-2和疹病毒的抗病毒活性.
- 动态组合化学为设计具有增强治疗潜力的新药衍生物提供了一种策略.
研究的目的:
- 设计和合成具有改进PDE抑制性能的动态组合二甲基衍生物 (DDD).
- 在体内小鼠模型中研究DDD的疗效,研究肠道失生症和循环胺诱导的免疫缺陷.
主要方法:
- 分子动力学方法和组合性化被用于DDD合成.
- 高性能液体染色学 (HPLC) 和光谱法用于衍生品分析和PDE抑制试验.
- 使用体内小鼠模型来评估药理效应,包括抗腹活性和免疫恢复.
主要成果:
- 分子建模预测了18个二皮里达摩尔衍生物的自我组装成稳定的超分子结构.
- 合成的DDD在低度 (0.05μM) 时显示出显著的PDE抑制.
- 在小鼠中使用DDD可逆转链胺诱导的大肠炎,防止体重减轻,并恢复由环胺抑制的免疫力.
结论:
- 在溶液中最大数量的二皮里达摩尔衍生物 (18) 对于最佳的PDE抑制至关重要.
- 动态组合衍生物 (DDD) 与纯二甲基相比,具有更高的药理疗效.
- 对于涉及肠道失调和免疫缺陷的疾病来说,DDD是一个有前途的治疗剂.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
254
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
254
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
648
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
648
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
257
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
257
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.0K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
657
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
657
01:23Dipeptidyl Peptidase 4 Inhibitors
262
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
262